1. Home
  2. KFS vs ALT Comparison

KFS vs ALT Comparison

Compare KFS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KFS
  • ALT
  • Stock Information
  • Founded
  • KFS 1989
  • ALT 1997
  • Country
  • KFS United States
  • ALT United States
  • Employees
  • KFS N/A
  • ALT N/A
  • Industry
  • KFS Property-Casualty Insurers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • KFS Finance
  • ALT Health Care
  • Exchange
  • KFS Nasdaq
  • ALT Nasdaq
  • Market Cap
  • KFS 417.8M
  • ALT 292.0M
  • IPO Year
  • KFS 1996
  • ALT N/A
  • Fundamental
  • Price
  • KFS $14.37
  • ALT $3.83
  • Analyst Decision
  • KFS
  • ALT Strong Buy
  • Analyst Count
  • KFS 0
  • ALT 6
  • Target Price
  • KFS N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • KFS 69.0K
  • ALT 3.0M
  • Earning Date
  • KFS 08-07-2025
  • ALT 08-12-2025
  • Dividend Yield
  • KFS N/A
  • ALT N/A
  • EPS Growth
  • KFS N/A
  • ALT N/A
  • EPS
  • KFS N/A
  • ALT N/A
  • Revenue
  • KFS $119,287,000.00
  • ALT $20,000.00
  • Revenue This Year
  • KFS N/A
  • ALT N/A
  • Revenue Next Year
  • KFS N/A
  • ALT $761,880.20
  • P/E Ratio
  • KFS N/A
  • ALT N/A
  • Revenue Growth
  • KFS 12.05
  • ALT N/A
  • 52 Week Low
  • KFS $7.06
  • ALT $2.90
  • 52 Week High
  • KFS $16.80
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • KFS 54.71
  • ALT 51.79
  • Support Level
  • KFS $13.96
  • ALT $3.35
  • Resistance Level
  • KFS $14.36
  • ALT $3.66
  • Average True Range (ATR)
  • KFS 0.38
  • ALT 0.19
  • MACD
  • KFS 0.05
  • ALT 0.07
  • Stochastic Oscillator
  • KFS 89.60
  • ALT 86.18

About KFS Kingsway Financial Services Inc. (DE)

Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: